Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

“We are particularly excited about the single-cell transcriptomics database we’re building with Boehringer Ingelheim to ... in addition to the company’s current headquarters in Cambridge, ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

German companies including Merck and ZEISS expressed strong confidence and high hopes for the Chinese market at the China ...

"We are particularly excited about the single-cell transcriptomics database we're building with Boehringer Ingelheim to ... in addition to the company's current headquarters in Cambridge, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...